TIDMEKF

RNS Number : 3230M

EKF Diagnostics Holdings PLC

23 May 2022

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Cancellation of Treasury Shares and TVR

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business , refers to its announcement dated 11 April 2022, surrounding the completion of the Company's buyback programme of 9,000,000 shares, currently held in Treasury. The Company confirms these shares will be cancelled with effect from 24 May 2022 (the "Cancellation").

Following the Cancellation, the Company's total issued share capital will consist of 454,930,564 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company will not hold any Ordinary Shares in treasury.

Therefore, the total number of voting rights in the Company will be of 454,930,564.

The above figure of 454,930,564 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 
EKF Diagnostics Holdings plc                                    www.ekfdiagnostics.com 
Mike Salter, CEO                                              Tel: +44 (0)29 2071 0570 
Marc Davies, CFO 
 
Singer Capital Markets (Nominated Adviser &                   Tel: +44 (0)20 7496 3000 
 Joint Broker) 
Aubrey Powell / George Tzimas 
 
Investec Bank plc (Joint Broker)                              Tel: +44 (0)20 7597 4000 
Gary Clarence / Daniel Adams / Ben 
 Farrow 
 
Walbrook PR Limited                     Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Applegarth                Mob: +44 (0)7980 541 893 / +44 (0)7584 
                                                                               391 303

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

 
 Point-of-Care            Providing a portfolio of Point-of-Care analysers and 
                           consumables, particularly for use in the area of Hematology 
                           and Diabetes, for use in hospital and research laboratories, 
                           doctor's offices, blood banks and for in-field anaemia 
                           screening programmes. EKF has an estimated 80,000 
                           hemoglobin, hematocrit, HbA1c, glucose and lactate 
                           analysers in regular use across more than 100 countries. 
 Central Laboratory       Clinical chemistry, Small lab analysers, Centrifuges 
                           Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycates 
                           Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin 
 Life Sciences            Enzyme fermentation, Custom products and Bulk fermentation 
 Contract Manufacturing   Bulk formulation, Sample collection kits, Private 
                           labelling, Molecular and forensic kits 
 Laboratory Services      In September 2021, EKF completed the acquisition of 
                           Advanced Diagnostic Laboratory LLC ("ADL Health") 
                           , a Texas based testing laboratory certified under 
                           the Clinical Laboratory Improvement Amendments ("CLIA") 
                           for high complexity testing. The laboratory provides 
                           testing for a variety of clinical, forensic and microbiological 
                           sample types using a range of analytical techniques. 
                           This acquisition positions EKF as a leading 'one stop' 
                           provider of diagnostic products and services from 
                           sample collection to results.

EKF's growth strategy to 2024 and beyond can be summarised as:

 
 --   continuing innovation in products and services in Point-of-Care, 
       Central Laboratory and Life Sciences leveraging new and existing 
       routes to market and relationships; 
 --   investment in expanded production and kitting capabilities to offer 
       a suite of diagnostic Contract Manufacturing solutions to third 
       party businesses; 
 --   expansion of CLIA Laboratories Testing offering, building on the 
       acquired capabilities in ADL Health; and 
 --   identify complementary earnings-enhancing acquisitions with key 
       strategic value.

EKF will also continue to generate enhanced shareholder value through:

 
 --   a progressive dividend policy; and 
 --   its agreement with Mount Sinai Innovation Partners ("MSIP"), which 
       allows us advanced access to innovative commercial opportunities 
       and where we can build on the ongoing successes of Renalytix plc, 
       Verici Dx plc and Trellus Health plc.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEASSEAFSAEFA

(END) Dow Jones Newswires

May 23, 2022 02:00 ET (06:00 GMT)

Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Ekf Diagnostics.
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Ekf Diagnostics.